Home LiteratureArticle Details
PMID: 8355677 Published · ppublish English Journal Article

Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression.

Molecular and cellular biology ·Vol. 13 ·No. 9 ·1993-09-00 ·Pages 5186-94

Unger T, Mietz JA, Scheffner M, Yee CL, Howley PM

Abstract

The wild-type (wt) p53 protein has transcriptional activation functions which may be linked to its tumor suppressor activity. Many mutant p53 proteins expressed in cancers have lost the ability to function as transcriptional activators and furthermore may inhibit wt p53 function. To study the mechanisms by which mutant forms of p53 have lost their transactivation function and can act in a dominant negative manner, a structure-function analysis of both mutant and engineered truncated forms of p53 was carried out. We show that different mutant p53 proteins found in cancers vary in the ability to inhibit the transcriptional transactivation and specific DNA binding activities of wt human p53. This transdominant effect was mediated through the carboxy-terminal oligomerization region. The role of the transactivation activity in transformation suppression by wt p53 was also examined by constructing an N-terminal deletion mutant lacking the transactivation domain. This mutant was unable to transactivate but could bind specifically to DNA. Although it was impaired in its ability to suppress transformation of primary rat embryo fibroblasts by adenovirus E1A plus activated ras, the N-terminal deletion mutant still had some suppression activity, suggesting that additional functions of p53 may contribute to transformation suppression.

MeSH Terms
Animals Base Sequence Cell Line Cell Transformation, Viral DNA-Binding Proteins/chemistry Genes, Dominant Genes, p53 In Vitro Techniques Molecular Sequence Data Mutagenesis, Site-Directed Oligodeoxyribonucleotides/chemistry Rats Sequence Deletion Structure-Activity Relationship Transcription, Genetic Transcriptional Activation Tumor Suppressor Protein p53/physiology
Chemicals
DNA-Binding Proteins Oligodeoxyribonucleotides Tumor Suppressor Protein p53
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Unger T
Laboratory of Tumor Virus Biology, National Cancer Institute, Bethesda, Maryland 20892.
Mietz J A
Scheffner M
Yee C L
Howley P M
References (60)
60 references, click to expand
  1. A potential transcriptional activation element in the p53 protein.
    Oncogene. 1990 Dec;5(12):1829-32 PMID: 2284102
  2. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.
    Science. 1990 Aug 31;249(4972):1049-51 PMID: 2144364
  3. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.
    Cell Growth Differ. 1990 Dec;1(12):571-80 PMID: 2288874
  4. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.
    Cell. 1991 May 31;65(5):765-74 PMID: 2040013
  5. The p53 tumour suppressor gene.
    Nature. 1991 Jun 6;351(6326):453-6 PMID: 2046748
  6. Identification of p53 as a sequence-specific DNA-binding protein.
    Science. 1991 Jun 21;252(5013):1708-11 PMID: 2047879
  7. The MCK enhancer contains a p53 responsive element.
    Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4570-1 PMID: 1647009
  8. p53 mutations in human cancers.
    Science. 1991 Jul 5;253(5015):49-53 PMID: 1905840
  9. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6.
    Nature. 1991 Jul 25;352(6333):345-7 PMID: 1852210
  10. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product.
    Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7605-9 PMID: 1652755
  11. A DNA binding domain is contained in the C-terminus of wild type p53 protein.
    Nucleic Acids Res. 1991 Oct 11;19(19):5191-8 PMID: 1923804
  12. Involvement of wild-type p53 in pre-B-cell differentiation in vitro.
    Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8982-6 PMID: 1924360
  13. Analysis of p53 mutants for transcriptional activity.
    Mol Cell Biol. 1991 Dec;11(12):6067-74 PMID: 1944276
  14. Wild-type p53 can down-modulate the activity of various promoters.
    Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):9979-83 PMID: 1946467
  15. Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F.
    Nature. 1992 Jan 9;355(6356):176-9 PMID: 1530885
  16. Temperature-sensitive mutants of p53 associated with human carcinoma of the lung.
    Oncogene. 1992 Jan;7(1):71-6 PMID: 1741167
  17. Formation of stable p53 homotetramers and multiples of tetramers.
    Mol Carcinog. 1992;5(2):102-6 PMID: 1554407
  18. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.
    EMBO J. 1992 Apr;11(4):1383-90 PMID: 1314165
  19. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.
    Nature. 1992 May 7;357(6373):82-5 PMID: 1533443
  20. Mammalian p53 can function as a transcription factor in yeast.
    Nucleic Acids Res. 1992 Apr 11;20(7):1539-45 PMID: 1579447
  21. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.
    Proc Natl Acad Sci U S A. 1992 May 15;89(10):4495-9 PMID: 1584781
  22. A transcriptionally active DNA-binding site for human p53 protein complexes.
    Mol Cell Biol. 1992 Jun;12(6):2866-71 PMID: 1588974
  23. Oncogenic forms of p53 inhibit p53-regulated gene expression.
    Science. 1992 May 8;256(5058):827-30 PMID: 1589764
  24. Amplification of a gene encoding a p53-associated protein in human sarcomas.
    Nature. 1992 Jul 2;358(6381):80-3 PMID: 1614537
  25. Wild-type p53 activates transcription in vitro.
    Nature. 1992 Jul 2;358(6381):83-6 PMID: 1614538
  26. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
    Cell. 1992 Jun 26;69(7):1237-45 PMID: 1535557
  27. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element.
    Genes Dev. 1992 Jul;6(7):1143-52 PMID: 1628822
  28. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization.
    Oncogene. 1992 Aug;7(8):1513-23 PMID: 1321401
  29. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
    Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6413-7 PMID: 1631137
  30. p53 function and dysfunction.
    Cell. 1992 Aug 21;70(4):523-6 PMID: 1505019
  31. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells.
    J Virol. 1992 Oct;66(10):6164-70 PMID: 1356162
  32. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.
    Genes Dev. 1992 Oct;6(10):1886-98 PMID: 1398068
  33. A new technique for the assay of infectivity of human adenovirus 5 DNA.
    Virology. 1973 Apr;52(2):456-67 PMID: 4705382
  34. T antigen is bound to a host protein in SV40-transformed cells.
    Nature. 1979 Mar 15;278(5701):261-3 PMID: 218111
  35. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.
    Cell. 1979 May;17(1):43-52 PMID: 222475
  36. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells.
    Cell. 1982 Feb;28(2):387-94 PMID: 6277513
  37. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene.
    Nature. 1982 Jun 10;297(5866):474-8 PMID: 6283357
  38. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
    Mol Cell Biol. 1982 Sep;2(9):1044-51 PMID: 6960240
  39. Activation of gene expression by adenovirus and herpesvirus regulatory genes acting in trans and by a cis-acting adenovirus enhancer element.
    Cell. 1983 Nov;35(1):127-36 PMID: 6313219
  40. Oligomerization of oncoprotein p53.
    J Virol. 1988 Dec;62(12):4737-44 PMID: 3054153
  41. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
    Science. 1989 Apr 14;244(4901):217-21 PMID: 2649981
  42. The p53 proto-oncogene can act as a suppressor of transformation.
    Cell. 1989 Jun 30;57(7):1083-93 PMID: 2525423
  43. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells.
    Nucleic Acids Res. 1989 Aug 11;17(15):6419 PMID: 2771659
  44. Wild-type p53 can inhibit oncogene-mediated focus formation.
    Proc Natl Acad Sci U S A. 1989 Nov;86(22):8763-7 PMID: 2530586
  45. p53: a frequent target for genetic abnormalities in lung cancer.
    Science. 1989 Oct 27;246(4929):491-4 PMID: 2554494
  46. Association of human papillomavirus types 16 and 18 E6 proteins with p53.
    Science. 1990 Apr 6;248(4951):76-9 PMID: 2157286
  47. Structural aspects of the p53 protein in relation to gene evolution.
    Oncogene. 1990 Jul;5(7):945-52 PMID: 2142762
  48. Presence of a potent transcription activating sequence in the p53 protein.
    Science. 1990 Aug 31;249(4972):1046-9 PMID: 2144363
  49. p53 functions as a cell cycle control protein in osteosarcomas.
    Mol Cell Biol. 1990 Nov;10(11):5772-81 PMID: 2233717
  50. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.
    Science. 1990 Nov 30;250(4985):1233-8 PMID: 1978757
  51. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.
    Nature. 1990 Dec 20-27;348(6303):747-9 PMID: 2259385
  52. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase.
    Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9210-4 PMID: 1409626
  53. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.
    Cell. 1992 Nov 13;71(4):587-97 PMID: 1423616
  54. Regulation of the specific DNA binding function of p53.
    Cell. 1992 Nov 27;71(5):875-86 PMID: 1423635
  55. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.
    Mol Cell Biol. 1992 Dec;12(12):5581-92 PMID: 1448088
  56. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.
    EMBO J. 1992 Dec;11(13):5013-20 PMID: 1464323
  57. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
    Mol Cell Biol. 1993 Jan;13(1):301-6 PMID: 8417333
  58. Regulation of the human hsp70 promoter by p53.
    Science. 1993 Jan 1;259(5091):84-7 PMID: 8418500
  59. Definition of a consensus binding site for p53.
    Nat Genet. 1992 Apr;1(1):45-9 PMID: 1301998
  60. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.
    Genes Dev. 1991 Feb;5(2):151-9 PMID: 1995413
Article Info
Journal
Molecular and cellular biology
Abbr.
Mol Cell Biol
ISSN
0270-7306
Published
1993-09-00
Pages
5186-94
Language
English
Region
United States
NLM ID
8109087
PMCID
PMC360207
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]